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Background: Early goal-directed therapy refers to the use of predefined hemodynamic goals to optimize tissue
oxygen delivery in critically ill patients. Its application in high-risk abdominal surgery is, however, hindered by safety
concerns and practical limitations of perioperative hemodynamic monitoring. Arterial waveform analysis provides
an easy, minimally invasive alternative to conventional monitoring techniques, and could be valuable in early
goal-directed strategies. We therefore investigate the effects of early goal-directed therapy using arterial waveform
analysis on complications, quality of life and healthcare costs after high-risk abdominal surgery.
Methods/Design: In this multicenter, randomized, controlled superiority trial, 542 patients scheduled for elective,
high-risk abdominal surgery will be included. Patients are allocated to standard care (control group) or early
goal-directed therapy (intervention group) using a randomization procedure stratified by center and type of surgery.
In the control group, standard perioperative hemodynamic monitoring is applied. In the intervention group, early
goal-directed therapy is added to standard care, based on continuous monitoring of cardiac output with arterial
waveform analysis. A treatment algorithm is used as guidance for fluid and inotropic therapy to maintain cardiac
output above a preset, age-dependent target value. The primary outcome measure is a combined endpoint of
major complications in the first 30 days after the operation, including mortality. Secondary endpoints are length
of stay in the hospital, length of stay in the intensive care or post-anesthesia care unit, the number of minor
complications, quality of life, cost-effectiveness and one-year mortality and morbidity.
Discussion: Before the start of the study, hemodynamic optimization by early goal-directed therapy with arterial
waveform analysis had only been investigated in small, single-center studies, including minor complications as
primary endpoint. Moreover, these studies did not include quality of life, healthcare costs, and long-term outcome
in their analysis. As a result, the definitive role of arterial waveform analysis in the perioperative hemodynamic
assessment and care for high-risk surgical patients is unknown, which gave rise to the present trial. Patient inclusion
started in May 2012 and is expected to end in 2016.
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Trial registration: This trial was registered in the Dutch Trial Register (registration number NTR3380) on 3
April 2012.
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High-risk surgery
Both the extent of the surgical procedure and the presence
of comorbidities increase the risk of an adverse outcome
after surgery. Moreover, approximately 12.5% of all surgi-
cal patients are considered as ‘high-risk’ [1,2]. The major-
ity of perioperative complications and death occur in this
minority of patients [1]. With increasing age and comor-
bidities in the general population, the number of high-risk
surgical patients is expected to grow. Approximately 50%
of these surgical patients develops one or more periopera-
tive complications, and mortality in this specific patient
group is around 5% [1-6]. Major complications such as
myocardial infarction, cardiac failure, stroke, pneumonia,
renal failure, or sepsis, involve a significant burden to the
patient and to hospital facilities during the hospitalization
period [3]. After discharge, these complications may result
in long-term disability, cognitive impairment and even
death, significantly reducing quality of life and increasing
healthcare consumption [3].Hemodynamic monitoring in high-risk surgery
Surgical patients are subject to the effects of anesthesia, dir-
ect surgical trauma, inflammation, fluid shifts, and blood
loss. In extensive surgical procedures these effects are en-
hanced, which may impair oxygen delivery to organs and
tissues. Patients with significant comorbidities have limited
cardiopulmonary reserve and are therefore more suscep-
tible to the consequences of surgical stress [7]. An imbal-
ance in tissue oxygen delivery and demand may occur,
which promotes the incidence of complications [8-10].
This emphasizes the need for appropriate hemodynamic
monitoring and optimization therapy to maintain ad-
equate tissue oxygen delivery in perioperative care for this
high-risk group.
Cardiac output (CO) is the principal determinant of
tissue oxygen delivery. Continuous monitoring of CO
would therefore be valuable for each high-risk surgical
patient. A number of CO measurement techniques are
available. Pulmonary artery thermodilution remained the
standard technique for a number of decades [11,12].
This technique is, however, invasive and associated with
potentially life-threatening complications which limits
its use in clinical practice [11,12]. Transesophageal echo-
cardiography (TEE) can be used to measure CO, but is
also rather invasive, does not provide CO continuously,and requires specific skills that are not included in the
training of each anesthesiologist or intensive care phys-
ician [13]. Therefore, TEE is predominantly used in car-
diac surgery. Esophageal Doppler probes for continuous
CO measurement are easier to use but not readily toler-
ated by conscious patients. Other minimally invasive CO
techniques such as bioimpedance are not yet sufficiently
reliable for use in clinical practice [13].
Arterial waveform analysis (AWA) provides a less inva-
sive and more practical alternative to conventional tech-
niques of CO monitoring. CO is derived from the arterial
pressure waveform and only requires an arterial line, which
is almost routinely placed in high-risk surgical patients in
the operating room (OR) and intensive care unit (ICU)
[13,14]. Moreover, the AWA technique enables dynamic
preload assessment in mechanically ventilated patients.
Assessment of cardiac preload or fluid responsiveness is
the first step in optimizing CO [14,15]. Both AWA-based
CO measurement and dynamic preload assessment have
been validated in a variety of clinical settings [14,16]. The
technique is therefore potentially valuable for advanced
hemodynamic monitoring and fluid optimization of high-
risk, non-cardiac surgical patients [17].
Early goal-directed therapy
Adequate strategies to correct and improve hemodynamic
variables should be available, since monitoring without
therapeutic consequences is not enough. Early goal-
directed therapy (EGDT) refers to the preemptive use of
predefined target values for hemodynamic optimization in
order to maintain tissue oxygen delivery. A target variable
is continuously monitored and immediately corrected
using a treatment algorithm if the value decreases below a
predefined threshold. Especially CO or CO-derived vari-
ables have been used for this purpose. The treatment algo-
rithms used in EGDT guide fluid therapy and inotropic
support, in order to improve the patient’s hemodynamic
status. With the emergence of AWA techniques, a new,
promising CO measurement technique became available
for EGDT [14,18].
Previous literature
Before the start of the study we performed a systematic re-
view of the literature to evaluate all available evidence on
the use of EGDT in elective, high-risk, abdominal surgery
(Additional file 1). The results indicated that EGDT is a
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in high-risk surgery. There are, however, several limita-
tions to the previous literature which may explain
why EGDT has never been widely implemented into rou-
tine practice [19]. First, the results from most studies are
outdated and not applicable to the current standard of
care. In studies from 1988 to 2000, morbidity and mortal-
ity are much higher in comparison with current practice,
even in the intervention groups. The same applies for
length of stay in the hospital. Second, pulmonary artery
catheterization has been used for the purposes of EGDT at
that time. As described before, this technique is limited to
specific types of surgery and not broadly accepted for peri-
operative monitoring in non-cardiac surgery [11-13,20].
Two studies applying arterial waveform analysis for
EGDT purposes were small and performed in a single
center [4,6]. Moreover, minor complications, such as
short-lasting intraoperative hypotension or urinary tract
infection, are included as an outcome measure. These
complications are not associated with increased long-term
morbidity and mortality and should be evaluated separ-
ately. One final but major limitation applies to all of the
studies described. They lack information about the effect
of EGDT on long-term outcome, quality of life, and
utilization of healthcare resources. This hinders a cost-
effectiveness analysis. EGDT requires the purchase of CO
monitoring equipment which consists of specific patient
monitors and arterial blood pressure sensors. Additional
costs may be the result of an increased use of inotropic
support or other therapeutic consequences of EGDT.
Since the start of the trial in May 2012, a number of in-
teresting studies have been published which partially ad-
dressed the shortcomings mentioned above [5,21-23]. Two
studies demonstrated that the implementation of a goal-
directed strategy was cost-effective [21,22]. In addition,
two multicenter studies were performed in which a reduc-
tion in complications was shown [5,23]. However, minor
complications were included, and the number of patients
was rather small in these studies.
Added value of the proposed study
The present study is a multicenter, randomized controlled
trial in a relatively large group of patients and performed
in both university and non-academic teaching hospitals.
Patients scheduled for elective high-risk abdominal surgery
are included. They represent an extensive group of patients
at risk for adverse postoperative outcomes. The primary
aim is to reduce the number of major complications that
are associated with an increased short-term and long-term
morbidity and mortality. These complications are expected
to comprise a major burden to quality of life, healthcare
costs, and long-term outcome, which are included as
secondary outcome parameters. AWA-based CO moni-
toring techniques are used to assess tissue oxygen delivery,which are minimally invasive and easy-to-use. The treat-
ment algorithm is straightforward and suitable for each
anesthesiologist, ICU physician, and anesthesia or ICU
nurse. The results of this study may therefore be useful in
guiding evidence-based implementation of EGDT.
Objective
The primary objective of the study is to investigate the ef-
fect of perioperative EGDT using arterial waveform analysis
on a composite endpoint of major complications, including
mortality after high-ris, abdominal surgery, in comparison
with standard care. Secondary endpoints are minor com-
plications, length of stay in the hospital, length of stay in
the ICU or post-anesthesia care unit (PACU), long-term
outcome, quality of life (QOL), and cost-effectiveness. We
hypothesize that perioperative EGDT using AWA reduces
the number of major complications after high-risk abdom-
inal surgery in comparison with standard care.
Methods/Design
Trial design
The EGDT trial is designed as a multicenter, randomized,
controlled superiority trial with two parallel groups in a
1:1 allocation. The trial is unblinded for the clinicians in-
volved, the patients, and the observers.
Study setting
Currently, the study is performed in three hospitals in
The Netherlands: Albert Schweitzer Hospital (Dordrecht,
The Netherlands), University Medical Center Groningen
(Groningen, The Netherlands), and University Medical
Center Utrecht (Utrecht, The Netherlands). The Maastricht
University Medical Center (Maastricht, The Netherlands)
is preparing study participation. Additional participating
centers may be added in the future.
Eligibility criteria
Eligible are patients scheduled for elective high-risk ab-
dominal surgery. Two groups of patients are considered
high-risk: patients undergoing extensive procedures com-
prising a high risk for an adverse postoperative outcome,
irrespective of the condition of the patient (group 1); pa-
tients undergoing moderately extensive procedures that
suffer from significant comorbidity (group 2). These pro-
cedures comprise a moderately high-risk for an adverse
postoperative outcome in healthy patients, but are consid-
ered high-risk for patients with significant comorbidity.
Inclusion criteria are:
1) Group 1: patients scheduled for the following
operations in which postoperative observation in the
ICU/PACU is needed, irrespective of their American
Society of Anesthesiologists (ASA, Table 1) physical
status: esophagectomy, pancreaticoduodenectomy,





I Normal, healthy patient
II Patient with mild systemic disease which does not
affect daily functioning (such as controlled hypertension,
stable chronic obstructive pulmonary disease (COPD),
well-regulated diabetes mellitus, mild obesity)
III Severe systemic disease which affects daily functioning
(such as coronary artery disease, heart failure or COPD
limiting exercise tolerance, morbid obesity)
IV Systemic disease that is a constant threat to life (such
as invalidating COPD or heart failure, unstable
angina pectoris)
V Moribund patient
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abdominal resections for soft tissue malignancy.
2) Group 2: patients with ASA physical status III or IV
scheduled for the following surgical procedures in
which postoperative observation in the ICU/PACU
is needed: gastrectomy, colorectal resections for
carcinoma, and other extensive upper or lower
abdominal surgery (such as ileocystoplasty or
debulking surgery for ovarian cancer).
Patients will be excluded if they meet one of the fol-
lowing criteria: patients with aortic insufficiency > grade
1, patients who are under 18 years-old, patients with car-
diac arrhythmias (such as atrial fibrillation or flutter, or
ventricular tachycardia), patients requiring emergency
surgery, patients in which cardiac output measurement
is mandatory for therapeutic decisions, or contraindica-
tion for passive leg raising in the entire postoperative
period.
Randomization
A randomization procedure is used to allocate patients
to standard care (control group) or standard care with
EGDT (intervention) in a 1:1 ratio. The randomization
is stratified according to hospital and type of surgery. In
each stratum, a block randomization with variable block
size is applied using a computer.
Standard care
Patients assigned to standard care will be treated according
to local routine, with the following conditions: 1) after in-
duction of anesthesia and tracheal intubation, patients are
mechanically ventilated (volume control) with a fixed tidal
volume of 8 ml/kg−1 (ideal body weight, IBW) throughout
the procedure, adjusting respiratory rate to maintain nor-
mocapnia; 2) an arterial line, central venous line, and
urine catheter are placed, 3) hypotension after induction
is treated preferably with crystalloids, eventually withcolloids, with a maximum of 500 ml. Ongoing hypotension
is treated with a continuous infusion of norepinephrine.
Sudden, short-lasting hypotension is treated with phenyl-
ephrine or ephedrine depending on local routine and
indication; and 4) transfusions with erythrocytes will be
applied according to the 4-5-6 rule (Additional file 2).
Therapy is aimed at maintaining: SpO2 ≥ 95%, mean ar-
terial blood pressure (MAP) ≥ 60 mmHg or ≤ 25% below
baseline in cases of preexisting hypertension, and heart
rate (HR) < 100/min or ≤ 25% above baseline.
The use of epidural analgesia, enhanced recovery after
surgery (ERAS) protocols, corrections for preoperative
fasting, and basic fluid regimes is allowed but not obliga-
tory. Serum lactate, central venous oxygenation satur-
ation, and other laboratory parameters may be used to
the discretion of the attending anesthesiologist or ICU
physician.
Intervention
Patients assigned to EGDT are treated according to the
same conditions as defined for the standard group. An
EGDT algorithm is added to standard care in order to
maintain tissue oxygen delivery in the perioperative period.
After induction of anesthesia in the OR, an AWA tech-
nique is applied for continuous CO measurement and dy-
namic preload assessment. The choice of AWA technique
depends on the institution in which the study is per-
formed. CO values are indexed to the patients’ body sur-
face area. For each patient, an age-dependent target
cardiac index (CI) is determined with the following cri-
teria: age < 60 years, target CI ≥ 2.8 l/min/m; age between
60 and 75 years, target CI ≥ 2.6 l/min/m; or age > 75 years,
target CI ≥ 2.4 l/min/m.
If the CI drops below the target value, a treatment al-
gorithm is used in order to restore the CI above the
threshold (Figure 1). In this algorithm, the dynamic pre-
load parameter stroke volume variation (SVV) is used to
determine whether the patient should receive a fluid
challenge (FC), or whether inotropic support should be
started or increased. Continuous infusion of norepineph-
rine and/or dobutamine should be used as inotropic sup-
port. SVV cannot be used in the following circumstances:
spontaneous breathing activity, tidal volume <8 ml/kg,
and/or breathing frequency >16/min−.
In these circumstances, a passive leg raising (PLR) test
is used to guide fluid or inotropic support [24-26]. The
procedure is explained in Figure 2. If the CI increases
10% or more during PLR, a 500 ml FC is given. If not,
inotropic support is started or increased. If both measure-
ment of SVV and PLR testing are not possible, a small
250 ml FC is given. If the CI subsequently increases, an-
other 250 ml FC is given. If the CI does not increase, ino-
tropic support is started or increased. Treatment according
to this EGDT algorithm starts after induction of anesthesia
Figure 1 EGDT algorithm. (1)target value depends on age: age < 60 years: target CI≥ 2.8 l/min/m2; age between 60 and 75 years: target CI ≥
2.6 l/min/m2; or age > 75 years: target CI ≥ 2.4 l/min/m2. (2)”no” in the presence of spontaneous breathing activity, tidal volume < 8 ml/kg, or
breathing frequency > 16/min. (3)CI increases: repeat FC. If not: increase inotropic support. CI = Cardiac Index, FC = Fluid Challenge, PLR = Passive
Leg Raising, SVV = Stroke Volume Variation, Tidal volumes are in ml/kg ideal body weight (IBW); IBW is calculated as 22 × L2 (L = length in meters).
Montenij et al. Trials 2014, 15:360 Page 5 of 12
http://www.trialsjournal.com/content/15/1/360in the OR and is maintained until discharge from the ICU/
PACU, with a maximum of 24 hours from induction of
anesthesia.
Modifications
In case of any newly developed arrhythmia in patients in
the intervention group, CO and SVV measurements ob-
tained with AWA are unreliable. Therefore, treatment
according to the EGDT algorithm stops as long as the
arrhythmia persists. If a patient in the intervention
group develops unwanted tachycardia, arrhythmia, or
(suspected) myocardial ischemia due to inotropic sup-
port applied within the EGDT algorithm, inotropic
support needs to be reduced or stopped, irrespective of
the CI. In addition, a FC should be withheld or stopped if
pulmonary edema or cardiac decompensation is sus-
pected, irrespective of the CI.Figure 2 Passive leg raising (PLR) test. The patient is transferred
to the PLR position, in which the legs are lifted at an angle of
45° for 120 seconds. This should be performed by pivoting the
entire bed.Protocol adherence
The EGDT algorithm is easy to use and rather straight-
forward, yet extensive training of nurses and physicians
involved in the care of patients allocated to EGDT will
be performed before the start of the study in each par-
ticipating center. Moreover, a number of nurses and
physicians from each institution have been involved in
the trial from the beginning and are thoroughly in-
formed about the procedures. These ‘trial experts’ can be
consulted at any time and will monitor the appropriate
application of the EGDT algorithm.
Outcome measures
The primary outcome measure is the number of major
complications per patient within the first 30 days after
surgery, including mortality. An overview of all major
complications can be found in Table 2. The complica-
tions within this composite endpoint are associated with
increased long-term morbidity and mortality [3].
The following secondary outcome measures are consid-
ered: the grade of major complications occurring in the
first 30 days after surgery according to the Accordion
Severity Grading system [31]; the number of the following
minor complications within the first 30 days after surgery:
arrhythmia (requiring intervention), deep venous throm-
bosis (confirmed by ultrasonography), urinary tract infec-
tion (confirmed by urinalysis and treated with antibiotics),
prolonged ileus (diagnose made and confirmed by sur-
geon), herniation or other prolonged wound healing (diag-
nosis made and confirmed by surgeon); the total amount
of fluid administered in the first 24 hours after surgery
(crystalloids, colloids, and blood products); inotropic
support in the first 24 hours after surgery (amount and
Table 2 Major complications within the first 30 days after surgery embedded in the composite primary endpoint
Category Complication Criteria
Mortality 30-day mortality Mortality within the first 30 days after surgery
Cardiovascular Cardiac arrest Cardiac arrest, electromechanical dissociation, ventricular fibrillation, or ventricular
tachycardia without output
Acute myocardial infarction According to the criteria for acute myocardial infarction (see Universal Definition
of Myocardial Infarction [27])
Acute pulmonary edema Diagnosis confirmed by X-ray
Stroke Focal brain injury that persists for >24 hours, combined with an increase in disability
of at least one grade on the modified Rankin scale [28], confirmed by cerebral CT-scan
Respiratory Prolonged mechanical ventilation Postoperative mechanical ventilation for more than 24 hours (any cause), including
non-invasive pressure support ventilation through a face-mask
Pulmonary embolism Confirmed by CT-scan
Pneumonia Confirmed by X-ray and treated with antibiotics
Respiratory failure Any other respiratory complication requiring mechanical ventilation
(including non-invasive pressure support ventilation)
Renal Acute kidney injury Stage 2 or 3 acute kidney injury, according to the Acute Kidney Injury Network [29]
Gastrointestinal Anastomotic leak Diagnose made and confirmed by surgeon
Other Any other complication requiring additional surgery
Infection Wound Diagnosis made and confirmed by surgeon
Severe sepsis See International Sepsis Definitions Conference [30]
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HR, CI, SVV, mean urine output) and laboratory (central
venous oxygen saturation and pCO2, serum lactate, tropo-
nin) variables in the first 24 hours after surgery; length
of stay in the hospital and in the ICU/PACU; continu-
ation of care at intermediate care units (level of care
in between the ward and ICU/PACU); number and length
of ICU/PACU or intermediate care readmissions; QOL;
cost-effectiveness; long-term outcome: 3, 6, and 12 months
complications and mortality.
Data collection
Before the operation demographic data, ASA physical sta-
tus, medical history, and drug usage are collected from
the patient’s medical records.
A number of hemodynamic variables (blood pressure,
HR, CI, and SVV if applicable) are recorded each hour
during the first 24 hours after induction. In the EGDT
group, these variables are also recorded before and after
interventions to correct a drop in CI below the target
value. Fluid balance in the first 24 hours is evaluated by
recording the amount of fluids infused (crystalloid, col-
loid, and blood products) as well as urine output and
blood loss. In addition, the use of inotropes is registered
(type, amount, and duration of infusion). The following
laboratory variables are determined after induction, dur-
ing surgical closure, after admittance to the ICU/PACU,
and the morning after surgery: serum hemoglobin, lactate,
and full blood gas analysis (arterial and venous). After ad-
mittance to the ICU/PACU, the following additional bloodvalues are determined in order to calculate the Sequential
Organ Failure Assessment (SOFA) score [32]: serum cre-
atinine, bilirubin, and platelet count. The morning after sur-
gery, serum troponin and creatinine levels are measured.
The Therapeutic Intervention Scoring System (TISS) is
calculated after admittance to the ICU/PACU [33]. Vari-
ables are derived from the patient monitoring systems
used in the operating room and ICU/PACU, or from the
OR and ICU/PACU record systems.
The following information is obtained in the first 30 days
after surgery: all-cause mortality, major and minor com-
plications, if applicable; duration of postoperative mechan-
ical ventilation (hours); length of stay in the in the hospital
(days) and ICU/PACU (hours); length of stay in the in the
hospital (days) and ICU/PACU (hours) according to fit-
for-discharge criteria [5] (Additional file 3); continuation
of care at intermediate care units (hours); number of read-
missions to the ICU/PACU or intermediate care unit.
All information can be obtained from the patients’
medical records. Patient follow-up with respect to com-
plications and length of stay is active.
QOL will be assessed with the EQ-5D and Short Form
(SF) 36 questionnaires before surgery and 1, 3, 6, and
12 months after surgery. Depending on the patient’s pref-
erence, the questionnaires are sent to the patient by email
or conventional mail, or the patient is called by an inter-
viewer. Patients who do not respond will receive a max-
imum of two phone calls as a reminder. Before contacting
or sending the questionnaires to the patient, confirmation
will be obtained that the patient is still alive.
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ment, hospital stay, and re-interventions) and non-healthcare
costs (costs as a result of absence from work) will be ana-
lyzed. Additional equipment and staff costs associated
with EGDT will be monitored to assess incremental costs
associated with EGDT. Direct healthcare costs will be cal-
culated by multiplying the volume of (healthcare) re-
sources use with its cost, using standard reference prices
for economic evaluation in healthcare whenever available.
Information on the following direct costs will be collected
from the medical records: blood sample measurements,
cultures and other investigations (such as chest films,
CT-scans, echography, and ECG), interventions (such as
reoperation, catheterization, chest drainage, and anti-
biotic treatment), and discharge destination (home, nurs-
ing home, rehabilitation). Data on absenteeism from work
will be collected using parts of the Short-Form Health and
Labor Questionnaire (SF-HLQ). The following three ques-
tions are added to the SF-HLQ: how many times did you
visit your general practitioner? How many times did you
visit a doctor in the hospital? Have you been admitted to
the hospital? These questions are included in the QOL
questionnaire described above. Indirect costs associated
with production losses will be estimated using the friction
cost method.
Long-term outcome is determined with a letter to the
general practitioner of the patient after 3, 6, and 12 months.
In this way, mortality and morbidity in the period between
30 days and one year after the operation is determined.
Statistical analysis and sample size calculation
A study of the hospital data of one of the participating
centers revealed that the number of major complications
embedded in the composite primary endpoint was 0.58
per patient, and that a Poisson distribution was applicable.
We aim to reduce the number of major complications per
patient by 30% (from 0.58 to 0.41). Using Poisson regres-
sion with an assumed two-sided error of 5%, we calculated
that a sample size of 226 patients in each group will be
needed to detect this reduction with a power of 80%. For
the multicenter character of the study, a 20% correction
was made, since the variance between the participating
centers is unknown. This results in a total sample size of
542, or 271 patients in each group.
Statistical analysis will be performed using SPSS
version 21.0 for Windows (SPSS Inc, Chicago, Illinois,
United States). The first analysis will be performed by
combining the results from the participating centers. After
this, the results of the individual centers are analyzed to
detect possible differences. The primary analysis consists
of a comparison of the primary endpoint (number of com-
plications per patient) between the control group and
the EGDT group using Poisson regression. According
to secondary endpoints, data will be checked for normaldistribution and presented as mean +/−standard devi-
ation when normally distributed, and as median +/−
interquartile range when not normally distributed. Relative
risks are presented with 95% confidence intervals. Categor-
ical data are tested with Fisher’s exact test. Continuous
data are tested with the independent samples t-test when
normally distributed, and with the Mann-Whitney U test if
not normally distributed. A P value <0.05 is considered sta-
tistically significant. Analysis will be carried out according
to the intention-to-treat principle.
For the quality-of-life assessment, the mean EQ-5D
score and the individual SF-36 subscale scores are deter-
mined, and a comparison will be made between the
standard group and the EGDT group. In addition, mean
change scores are determined and evaluated over time. For
the economic evaluation, especially the EQ-5D, is of im-
portance as utilities and consequently, quality-adjusted life
years (QALY), can be elicited using this generic quality-of-
life questionnaire. The incremental cost-effectiveness ratio
(ICER) will be expressed as cost differences between
groups divided by differences in numbers of serious com-
plications between groups (cost per complication averted).
The incremental cost-utility ratio (ICUR) will be expressed
as cost differences between groups divided by differences
in QALY’s gained between groups (cost per QALY). Confi-
dence intervals will be determined using bootstrapping. A
cost-effectiveness acceptability curve will be drawn using
this bootstrap sample.
Institutional Review Board approval and informed
consent
The trial has been reviewed and approved by the institu-
tional review board (IRB) of the University Medical Center
Utrecht (The Netherlands). Furthermore, local IRB ap-
proval has been obtained in the participating centers for
the local applicability of the protocol. Details regarding
the IRB approval are presented in Additional file 4. Writ-
ten informed consent will be obtained from all patients.
Risk assessments
The treatment algorithm introduced in the patients
assigned to EGDT includes measurement of cardiac out-
put, SVV, and PLR as a test. These measurements are
performed using the arterial catheter, which is routinely
placed in patients undergoing high-risk, non-cardiac sur-
gery. Therefore, no additional catheters are placed in com-
parison with routine hemodynamic monitoring. EGDT
involves fluid therapy and inotropic support, which are
commonly used in patients undergoing high-risk surgery.
Additional risk associated with its use in the treatment al-
gorithm is therefore not likely in comparison with routine
practice. The systematic review of the literature performed
before this study (Additional file 1) reported adverse
events due to the use of pulmonary artery catheters, which
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cardial ischemia due to use of inotropic support, which
disappeared after stopping inotropic infusion [6]. In the
other studies however, the results point to a lower inci-
dence of myocardial ischemia, although significant reduc-
tions have not been reported. Adverse events with respect
to fluid overload have not been described in the systematic
review. Despite this, precautions have been taken in the
EGDT algorithm to prevent the potentially harmful effects
of excessive fluid and inotropic support.
Safety procedure
Events that meet the criteria for ‘severe adverse events’
(SAE’s) are monitored and reported to the accredited
IRB that approved the protocol and to a Data Safety
Monitoring Board (DSMB). The major complications
embedded in the primary outcome measure meet these
criteria and are considered ‘expected SAE’s’. Cumulative
data on these expected SAE’s are reported biannually.
Mortality and all other ‘unexpected SAE’s’ are reported
immediately. The DSMB has been created to assess the
safety of the interventions and to monitor the overall
conduct of the study. In addition, the DSMB assists and
advises the investigators in protecting the validity and
credibility of the trial. The members of the DSMB for
this trial are an epidemiologist and biostatistician, an
anesthesiologist and intensivist, and a gastrointestinal sur-
geon. The DSMB members will meet every six months in
closed and open sessions. After each meeting the DSMB
may decide the following: the trial is allowed to continue
without further action, the trial is allowed to continue
with recommendations which will be evaluated in the next
meeting, or recruitment of patients is stopped since accu-
mulating data points to an adverse effect in the interven-
tion arm. The study will not stop if accumulating data
points to a beneficial effect in the intervention arm. The
roles and responsibilities of the DSMB are described in
detail in a DSMB charter.
Discussion
Trial context
There is an urgent need for a multicenter, randomized
controlled trial, evaluating the application of AWA-
based hemodynamic monitoring in goal-directed strat-
egies for high-risk surgical patients [14,34,35]. Ideally,
the algorithm used for EGDT should be user-friendly
and easily applicable in order to enhance the implemen-
tation in daily care. Moreover, this trial should include a
large group of patients in order to have sufficient power
to demonstrate differences in clinically relevant outcome
parameters. Finally, long-term effects in terms of QOL
and healthcare costs should be considered. So far, this
‘ideal’ trial has not been performed. The presented study
protocol attempts to include the important featuresmentioned, however, a number of aspects of the trial de-
sign however need to be discussed in detail. First we try
to elucidate the clinical choices made in the selection of
patients, the EGDT algorithm, care in the control group,
and safety. Next, we will discuss a number of methodo-
logical issues with respect to the study design, primary
outcome measure, blinding, and discharge criteria.
Clinical considerations
Patient population
Each year a large number of patients are scheduled for
extensive abdominal surgery in a variety of hospitals.
The postoperative problems seen in the postoperative
period involve a major burden to patients and healthcare
costs, and are acknowledged by many clinicians in the field
of anesthesia, critical care, and surgery. Yet there is on-
going debate if and which type of advanced hemodynamic
monitoring should be applied in these patients. In contrast,
transesophageal echocardiography and pulmonary artery
catheterization are extensively used in patients undergoing
cardiac surgery, while the risk for postoperative complica-
tions or mortality is often lower. Therefore, we chose
major abdominal surgery as the target population in this
study. Hepatic resections are considered high-risk abdom-
inal surgery, especially due to bleeding complications.
Intraoperatively, however, the use of fluids is highly
restrictive and the algorithm described in this study is not
suitable for application in this specific patient category.
Therefore, we decided to exclude patients scheduled for
hepatic resection.
EGDT algorithm
The algorithm was designed to be as easy as possible, to
enhance the applicability in the various types of hospitals
performing high-risk abdominal surgery. Basically, the
algorithm includes three steps: 1) detect a drop in CI
below the target value, 2) determine the intervention to
restore the CI, and 3) evaluate if the CI increases above
the target value.
The AWA technique used is not prescribed, but de-
pends on the preference of the hospital. This will en-
hance the willingness to implement EGDT in clinical
practice, since many hospitals already have AWA moni-
toring systems for other clinical purposes. In addition,
EGDT is the intervention under investigation, not a spe-
cific device. AWA algorithms continue to improve and
new devices will emerge in the coming years [36,37].
We decided to use CO, indexed to Body Surface Area
(BSA(m2) = 0.20247 × Height(m)0.725 × Weight(kg)0.425),
as the target variable in the EGDT algorithm. CO grad-
ually decreases with increasing age [38,39]. Since age
varies considerably in the target population, we decided
to use different target CI values in three age categories.
Assessment of fluid responsiveness is the first step in
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this purpose, if a number of criteria for mechanical ven-
tilation are met [14,15]. In the OR, this will be the case
in most situations. In the ICU or PACU however, pa-
tients are weaned from the ventilator, which hinders the
reliability of dynamic preload assessment. In these cir-
cumstances, PLR testing provides a suitable alternative,
if properly performed [24-26]. If the SVV criteria are not
met and PLR testing is not possible, we decided to use a
small FC to prevent unwanted volume loading in unre-
sponsive patients. This small FC can be repeated if the pa-
tient responds well. Otherwise, inotropic support is used
to restore the CI. Overall, SVV and PLR testing are im-
portant in the algorithm, which emphasizes the role of
cardiac preload in treating low CO. Preload optimization
is, however, not the primary target in this trial, since CO
represents the most direct way to determine tissue oxygen
delivery in the perioperative period [13].
Central venous oxygen saturation (ScvO2) has been
shown to be effective as a target variable in a number of
goal-directed strategies in critical care, and has been
considered as target variable for this trial as well [40-43].
There are, however, a number important limitations. For
proper interpretation, oxygen consumption should be
considered, which varies in the perioperative period to a
great extent [40]. In addition, ScvO2 is usually intermittently
determined, since special oximetry probes are needed for
continuous ScvO2 measurement. Therefore, ScvO2 was not
chosen as target in the treatment algorithm, but may be
used additionally according to local practice.
The EGDT algorithm starts in the OR after induction
of anesthesia before the start of surgery. Postoperatively
in the ICU/PACU, EGDT continues until discharge for a
maximum of 24 hours. In most hospitals, it is common
practice to monitor patients after high-risk surgery for
this period. For practical reasons therefore, EGDT can
easily be implemented. More importantly, impaired tis-
sue oxygenation may present up to 24 hours after sur-
gery [44-46].
Standard care
We decided to limit the criteria for standard care in order
to keep care in the control group close to local routine. As
described above, EGDT is meant as a supplement to stand-
ard care, not as a substitute. For reasons of generalizability
to other institutions, care in the control group should not
deviate from local routine to a great extent. On the other
hand, bias or major differences between the participating
centers may occur if standard care is rather heterogeneous.
Criteria for mechanical ventilation were introduced to
prevent bias from differences between the groups, since a
reliable SVV measurement requires specific ventilation
settings [14,15]. The other criteria are very routine in
most institutions. The use of epidural analgesia, enhancedrecovery after surgery (ERAS) protocols, corrections for
preoperative fasting, and basic fluid regimes are not ob-
ligatory. Due to randomization, these treatment elements
are expected to be balanced between the control and
intervention groups. In addition, these elements do not
interfere with the application of EGDT.
It would be valuable to monitor CO in the control
group as well, albeit blinded for the clinicians. The pres-
ence or absence of differences in outcome between the
control and intervention group are easier to interpret in
the light of differences in CO between the groups. In clin-
ical practice however, it may be difficult to apply standard
care in the control group in the presence of a CO monitor.
We fear that clinicians may tend to take CO values into
consideration in their therapy. In addition, CO monitoring
is associated with significant costs, which increases the
total costs of the trial to a great extent.
Safety
Our systematic review of the literature did not reveal any
harm due to the use of fluid or inotropes in goal-directed
strategies. In the OR and ICU/PACU, both fluid and ino-
tropes are extensively used. We decided to allow the use
of both crystalloid and colloid fluids, according to local
preferences. Norepinephrine and dobutamine were chosen
for inotropic support as these inotropes are commonly
used. Clinicians and other healthcare personnel are there-
fore familiar with the administration, clinical effects, and
adverse reactions. In the algorithm however, patients may
end up in a continuing loop of fluid or inotropic support
if the response in CI is insufficient. In this case, volume
overloading or adverse effects of inotropes may occur, and
a number of safety measures have been incorporated in
the algorithm in order to address this. If tachycardia,
arrhythmia, myocardial ischemia, pulmonary edema, or
cardiac decompensation is suspected or observed, any
intervention within the algorithm should be stopped im-
mediately. In contrast, fluid or inotropes should not be
withheld in patients with CI values above their target. We
therefore emphasize that EGDT is added to standard care
and does not replace it. Interventions within the usual
care for high-risk surgical patients, such as treatment of
hypotension, hypovolemia, or any other suspicion of
hemodynamic deterioration, should therefore be applied
irrespective of the CI or the treatment algorithm.
Methodological aspects
RCT design
Especially in studies evaluating perioperative hemodynamic
therapy, randomized controlled trials (RCTs) have a
number of limitations, such as impossibility to blind at the
patient and caregiver level, and the Hawthorne effect
[34,47,48]. The Hawthorne effect is a phenomenon whereby
clinicians tend to improve care for patients included in
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intervention groups [49]. We discussed the alternative ap-
proach of a before-after study. For the purposes of our
study, prospective data collection is necessary. Therefore,
the Hawthorne effect will be present in both ‘before’ and
‘after’ periods. More importantly, postoperative outcome
after high-risk surgery is multifactorial. It is simply impos-
sible to keep all these factors constant during the entire
study period, which was the main reason for choosing the
RCT design. Since the start of our trial, a number of im-
portant aspects in the care for high-risk surgical patients
have changed. First, robotic surgery is increasingly being
used in our institutions. Second, surgical safety checklists
have been introduced in many centers, reducing both
mortality and morbidity after surgery [50]. In one of the
participating centers in this trial this led to a signifi-
cant reduction in 30-day in-hospital mortality [51]. Similar
checklists have been implemented in the other participat-
ing centers. We therefore regarded randomization to be
crucial in this study. We stratified the randomization
procedure with respect to participating center and type
of surgery, since these covariates may influence outcome
to a great extent. The number of patients in certain strata
may become small however, which was the reason for ap-
plying blocked randomization.
Primary endpoint
The primary outcome measure in this trial is a combined
endpoint of major complications in the first 30 days after
surgery, including mortality. The use of composite end-
points in trials is common in order to increase statistical
power and to capture the net benefit of the intervention
[52,53]. The most important disadvantage of this approach
is that interpretation of the results is difficult if the out-
comes are of different importance to patients. The com-
ponents of a composite endpoint should therefore be
clearly defined, clinically important, effected by the inter-
vention, as homogeneous as possible, and weighed to re-
flect their relative importance [53].
The major complications embedded in the composite
endpoint in our study are clearly defined and associated
with increased long-term morbidity and mortality. Yet
there are differences in terms of clinical consequences
for the patient. Therefore, we decided to take the num-
ber of complications per patient as a primary endpoint,
instead of the number of patients with one or more
complications. In this way, the severity of the complica-
tion is reflected. For instance, if a patient develops pneu-
monia, which is treated with antibiotics in the ward, there
is only one complication registered. If the patient however
needs ICU readmission because of respiratory failure and
septic shock, three complications are registered. We will
report all complications separately to show if a difference
in the primary endpoint is predominantly caused by oneor more specific complications. In addition, the complica-
tions will be weighed using the Accordion complication
severity score [31].
A number of other outcome measures have been con-
sidered as a primary endpoint in this trial. First, we per-
formed a sample size calculation for the detection of a
difference in mortality. This however revealed that over
5,000 patients would be needed, which was not feasible.
Second, we calculated that approximately 250 patients
would be needed to detect a difference in length of stay in
the hospital. As a result, the study would have insufficient
power to detect differences in terms of morbidity, which
was our primary aim. Third, a single complication taken as
an outcome measure was considered. In this case, however,
consequences for the patient may differ considerably as
well. As described previously, pneumonia may have a mild
clinical course, but may also result in septic shock with
multi-organ failure. Finally, we considered complications
weighed according to the Accordian complication severity
score as a primary outcome measure [31]. This, however,
requires an ordinal approach to data-analysis, which is not
straightforward. In addition, it remains difficult to compare
patients with multiple complications.
Blinding
Ideally, blinding is used at the level of the patient, the
caregiver, and the assessor of the outcome variable. In
our trial however, blinding at the patient and caregiver is
simply impossible. In theory, it is possible to use blinded
assessors to determine outcome measures according to
specified criteria. However, patient follow-up should be
active and thorough, in order not to overlook complica-
tions and adverse outcomes once the patient is in the
ward or at home. This requires frequent visits to the pa-
tients and monitoring of the patients’ medical records.
During these visits and in these records, information
about the use of CO monitoring and PLR testing is easily
obtained, which makes blinding impossible. Therefore, all
variables are elaborately defined, especially outcome pa-
rameters. Strict criteria are used to define the complica-
tions embedded in the composite primary endpoint. In
this way, we aim to minimize bias as much as possible.
Discharge criteria
The length of stay in the hospital and ICU/PACU are im-
portant secondary endpoints, since they reflect the clinical
course in the postoperative period and represent a signifi-
cant part of the healthcare costs per patient. The dis-
charge from patients from the hospital or ICU/PACU is,
however, not only based on medical conditions but also
influenced by the availability of care at the discharge des-
tination. Continuation of care after treatment in the ICU/
PACU depends on the capacity of the wards or intermedi-
ate care units. Discharge from the hospital may require
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homes. In addition, discharge from the IC/PACU occurs
mainly the morning after surgery, which leads to a skewed
distribution. To account for these effects, fit-for-discharge
criteria from the hospital and ICU/PACU were deter-
mined (Additional file 3) [5].
Trial status
Patient recruitment started in May 2012 and is expected
to end in 2016. At the end of 2013, approximately 160
patients had been recruited across three centers. The
fourth center is expected to start patient recruitment in
2014.
Additional files
Additional file 1: Systematic review of the literature, performed
before the start of the study.
Additional file 2: The ‘4-5-6’ rule for transfusion with erythrocytes
during acute, normovolemic anemia.
Additional file 3: Fit-for-discharge criteria ICU/PACU.
Additional file 4: IRB approval information.
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